Compare Indoco Remedies with TVS SRICHAKRA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TVS SRICHAKRA - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TVS SRICHAKRA INDOCO REMEDIES/
TVS SRICHAKRA
 
P/E (TTM) x 128.4 11.3 1,137.3% View Chart
P/BV x 2.2 1.9 113.1% View Chart
Dividend Yield % 0.6 2.2 28.7%  

Financials

 INDOCO REMEDIES   TVS SRICHAKRA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
TVS SRICHAKRA
Mar-19
INDOCO REMEDIES/
TVS SRICHAKRA
5-Yr Chart
Click to enlarge
High Rs3173,765 8.4%   
Low Rs1782,170 8.2%   
Sales per share (Unadj.) Rs113.13,173.6 3.6%  
Earnings per share (Unadj.) Rs4.5134.8 3.3%  
Cash flow per share (Unadj.) Rs11.8245.5 4.8%  
Dividends per share (Unadj.) Rs1.0040.00 2.5%  
Dividend yield (eoy) %0.41.3 29.9%  
Book value per share (Unadj.) Rs73.2950.7 7.7%  
Shares outstanding (eoy) m92.157.66 1,203.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.9 234.3%   
Avg P/E ratio x55.522.0 252.0%  
P/CF ratio (eoy) x21.012.1 173.5%  
Price / Book Value ratio x3.43.1 108.4%  
Dividend payout %22.429.7 75.5%   
Avg Mkt Cap Rs m22,83022,730 100.4%   
No. of employees `0005.52.7 202.0%   
Total wages/salary Rs m2,2092,813 78.5%   
Avg. sales/employee Rs Th1,910.19,003.6 21.2%   
Avg. wages/employee Rs Th405.01,041.8 38.9%   
Avg. net profit/employee Rs Th75.5382.5 19.7%   
INCOME DATA
Net Sales Rs m10,41924,310 42.9%  
Other income Rs m47120 39.1%   
Total revenues Rs m10,46624,430 42.8%   
Gross profit Rs m1,3492,618 51.5%  
Depreciation Rs m677848 79.9%   
Interest Rs m235357 65.9%   
Profit before tax Rs m4841,533 31.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m72500 14.5%   
Profit after tax Rs m4121,033 39.9%  
Gross profit margin %12.910.8 120.3%  
Effective tax rate %15.032.6 45.8%   
Net profit margin %4.04.2 93.0%  
BALANCE SHEET DATA
Current assets Rs m5,3739,258 58.0%   
Current liabilities Rs m4,1578,815 47.2%   
Net working cap to sales %11.71.8 641.1%  
Current ratio x1.31.1 123.1%  
Inventory Days Days6875 90.5%  
Debtors Days Days7351 144.1%  
Net fixed assets Rs m6,2446,902 90.5%   
Share capital Rs m18477 240.6%   
"Free" reserves Rs m6,5667,206 91.1%   
Net worth Rs m6,7507,283 92.7%   
Long term debt Rs m1,233469 263.0%   
Total assets Rs m12,36318,093 68.3%  
Interest coverage x3.15.3 57.8%   
Debt to equity ratio x0.20.1 283.7%  
Sales to assets ratio x0.81.3 62.7%   
Return on assets %5.27.7 68.1%  
Return on equity %6.114.2 43.0%  
Return on capital %9.024.4 36.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7622,424 155.2%   
Fx outflow Rs m1,1433,550 32.2%   
Net fx Rs m2,619-1,127 -232.5%   
CASH FLOW
From Operations Rs m1,227640 191.7%  
From Investments Rs m-1,360-1,204 113.0%  
From Financial Activity Rs m-388524 -74.0%  
Net Cashflow Rs m-521-40 1,298.3%  

Share Holding

Indian Promoters % 59.2 45.4 130.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 2.6 480.8%  
FIIs % 6.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 52.1 43.0%  
Shareholders   12,805 23,740 53.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   GEOJIT FINANCIAL SERVICES  GREENPLY INDUSTRIES  TATA INVESTMENT  IIFL HOLDINGS  KOTHARI PRODUCTS  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

TVS SRICHAKRA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 19, 2019 | Updated on Aug 19, 2019

Here's an analysis of the annual report of TVS SRICHAKRA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TVS SRICHAKRA. Also includes updates on the valuation of TVS SRICHAKRA.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS